FDA Approves FLUTICASONE PROPIONATE — Glenmark Pharmaceuticals Inc., USA

Glenmark Pharmaceuticals Inc. has received a final FDA approval for the ANDA for Fluticasone Propionate Nasal Spray, which is set to expand its portfolio in a market currently driven by demand for effective over-the-counter allergy treatments. This approval positions Glenmark to compete for market share against established asthma and allergy franchises at a time when brand exclusivity for major competitors is nearing expiration.